tbuckley/cabot-search huggingface dataset:
Neoadjuvant chemotherapy using concurrent docetaxel/CDDP/5-FU (DCF) in esophageal squamous cell carcinoma and its excellent short-term prognosis.
Authors: Keishi Yamashita, Natsuya Katada, Chikatoshi Katada, Kei Hosoda, Hiomitsu Moriya, Katsuhiko Higuchi, Wasaburo Koizumi, Masahiko Watanabe
Journal: Journal of Clinical Oncology (2013)

e15122 Background: Neoadjuvant chemotherapy (NAC) using 5-FU/CDDP (FP) followed by surgery is a standard treatment for esophageal squamous cell carcinoma (ESCC). However, this therapy often encountered progression during the early course of treatment. We are developing the novel NAC using Docetaxel/CDDP/5-FU (DCF). Methods: Thirty eight patients who underwent DCF NAC in cStage II/III ESCC was compared with the 41 counterparts treated by FP NAC. Docetaxel and CDDP were both given to 70-75 mg/ m 2 with concurrent 5-FU at 750 mg/m 2 in 3 cycles. Median follow-up term of DCF NAC reached 18 months. Results: In DCF NAC, grade 3 adverse effects (AEs) were recognized in 97% (37/38), however non-hematological AEs exhibited 8% in stomatitis and 5% in anorexia, and completion rate of the DCF NAC was 86 %. In terms of PR+CR rate, DCF NAC was remarkably more excellent (33/38: 86.8%) than FP NAC (24/41: 58.5%)(P=0.0050). In DCF NAC therapy, 30 patients underwent surgery including 24 R0 esophagectomy, whereas another 8 patients selected definitive chemoradiation therapy. We experienced 3 patients with a pathologic complete response (ypCR)(10%) in DCF NAC. The 1 st univariate prognostic analysis for progression free survival (PFS) among all the cases with NAC revealed that significant factors were R0 resection (P&lt;0.0001), cT factor (P=0.0098), and NAC modality (P=0.1), and multivariate proportional hazard model identified these 3 factors as independent prognostic factors (IPFs). We then performed the 2 nd stage multivariate prognostic analysis limited to R0 cases including pathologic factors for PFS. The univariate negative prognostic factors were FP NAC (P=0.0064), ypT3 (P=0.032), ypN3 (P=0.0017), ypv2/3 (P=0.0072), as well as cT3 (P=0.033), and multivariate analysis identified only NAC modality. DCF NAC was significantly associated with less frequency of ypT3 (P=0.019) and ypv2/3(P=0.013). Conclusions: Novel DCF NAC for ESCC demonstrated high response rates, and is promising for excellent survival in R0 cases, with acceptable feasibility. It improved the patient survival through downstage of the significant prognostic factors.
Monitoring <i>PIK3CA</i> mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3Kα–inhibitor plus letrozole (L) or exemestane (E).
Authors: Mary Ellen Moynahan, Patricia Sung, Michael Asham, Stephen Zamora, Payal Deepak Shah, Shanu Modi, Diana Lake, Gabriella D'Andrea, Shari Beth Goldfarb, Sarat Chandarlapaty, Clifford A. Hudis, Jose Baselga, Maura N. Dickler, Sujata Patil, Alice A. Gaskell
Journal: Journal of Clinical Oncology (2014)

517 Background: In tumors that harbor activating mutations, tumor-derived cfDNA extracted from patient plasma can be serially quantified by droplet digital PCR (ddPCR). Mutant AF may be predictive of target-directed therapy for initial response and evolving resistance. We report results of a correlative aim assessing serial mutant AF in a phase I study of a PI3Kα-inhibitor, BYL719, with L or E in MBC. Methods: PIK3CA status was mutant/wild-type/unknown in 8/5/1 pts as determined by molecular analysis of tumor. Plasma samples were collected at baseline and on day 1 of each 28 day cycle while on protocol. cfDNA was extracted using QIAamp Circulating NA kit and quantified by KAPA hgDNA qPCR. Allele specific assays for PIK3CA E542K, E545K, H1047R and H1047L mutations were designed for quantification on BioRad QX200 Droplet Digital PCR System. Mutant AF is determined from the counts for mutant as compared to wild-type. The detection limit for each assay is calculated from the number of events detected. All sample runs are replicated. Results: 5/8 pts with PIK3CA mutation were evaluable by ddPCR having received treatment for at least 2 cycles with the PI3Kα-inhibitor. In the plasma of 4 pts, we identified a brisk decrease in PIK3CA mutant AF at cycle 2, day 1(C2D1) ranging from 91.8 - 99.6% decrease from baseline. All 4 pts had stable or responding disease as best response. In 1 patient, later determined to have disease progression there was a small change (19% decrease) in PIK3CA mutant AF at C2D1 with a 16X increase in mutant AF at C3. Ongoing responses result in a persistent low (>98% decrease) or undetectable mutant allele. In 1 patient, with a transient response, the marked decrease in mutant AF at C2D1 was followed by an increase at C3 predicting her clinical progression. Conclusions: Targeted therapies directed towards specific oncogene mutations may be assessed serially by ddPCR to confirm mutant target sensitivity. Assessment for early tumor resistance may allow a more rapid treatment change with real-time monitoring of target mutant alleles. Serial assessment may be helpful in the exploration of best and better tolerated dosing schedules. Clinical trial information: NCT01870505.
Baseline Clinical and Laboratory Parameters Associated with Clinical Benefits of Successful HCV Treatment with Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients
Authors: J. O’Leary, R.S. Brown, K.R. Reddy, J. Fenkel, K. Korenblat, Z.H. Younes, R. Herring, D. An, A. Osinusi, J. McNally, D. Brainard, J. McHutchison, M.P. Curry, M. Charlton
Journal: Journal of Hepatology (2016)
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015
Authors: Antonio Palumbo, Zdenek Adam, Martin Kropff, Robin Foà, John Catalano, Heinz Gisslinger, Wieslaw Wiktor-Jedrzejczak, Michel Delforge, Katja Weisel, Nicola Cascavilla, Jan Van Droogenbroeck, Genadi Iosava, Michele Cavo, Joan Blade, Meral Beksac, Ivan Spicka, Torben Plesner, Zhinuan Yu, Lindsey Herbein, Jay Mei, Christian J. Jacques, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
Autoreactive Iga Antibodies against the Pancreatic Major Glycoprotein 2 are Associated with Primary Sclerosing Cholangitis and Related Biliary Tract Cancer
Authors: S.T. Jendrek, D. Gotthardt, T. Nitzsche, T. Korf, M.A. Michaels, K.-H. Weiss, E. Liaskou, M. Vesterhus, T.H. Karlsen, S. Mindorf, P. Schemmer, F. Bär, T. Schröder, M. Ehlers, C.M. Hammers, L. Komorowski, H. Lehnert, K. Fellermann, S. Derer, J.R. Hov, C. Sina
Journal: Journal of Hepatology (2016)
Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy.
Authors: Satu Mustjoki, Tuisku Laurinolli, Marja Ekblom, Auvo Rauhala, Marjatta Sinisalo, Anders Almqvist, Elli Koivunen, Tuija Lundan, Freja Ebeling, Perttu Koskenvesa, Henrik Hjorth-Hansen, Petteri Arstila, Leif Stenke, Juan Luis Steegmann, Martin Hoglund, Bengt Simonsson, Neil Shah, Ronald Paquette, Kimmo Porkka
Journal: Blood (2007)
Resistin Prevents Visfatin Hepatic Recaptation from Adipose Tissue Inhepatic Surgery under Vascular Occlusion
Authors: M.E. Cornide-Petronio, E. Bujaldon, M. Mendes-Braz, M.B. Jiménez-Castro, E. Negrete-Sánchez, C.Á. de León, A. Casillas-Ramírez, J. Gulfo, J. Gracia-Sancho, J. Rodés, C. Peralta
Journal: Journal of Hepatology (2016)
Preparing nurses for cancer survivorship care.
Authors: Mary S. McCabe, Denice Economou, Marcia Grant
Journal: Journal of Clinical Oncology (2016)

27 Background: Although the 2006 IOM report on Cancer Survivorship calls for the education of health professionals, few formal programs have been instituted and evaluated. This NCI R25 grant focused on the preparation of nurses to provide comprehensive survivorship care. The program included didactic and interactive sessions, as well as goal development focused on plans for implementation of survivorship activities post course. This abstract will describe the goal analysis at 6, 12, and 18 months post course provided by the 113 nurses in the first two courses. Methods: Goals focused on survivorship activities to be implemented at the home institution/practice. Goals were coded using the results-based S.M.A.R.T. framework and they could have more than one code if they reflected multiple activities. Goal achievement was measured using a 5 point scale with 0 = never started, 1 = stopped or cancelled, 2 = Stalled, 3 = In Process or 4 = Completed at 6, 12 and 18 months post course. Results: A total of 403 goals were coded for the first 2 courses. The most frequent goal for both courses was Professional Education (23.1%, 21%). The second most frequent goal was -Institution of Survivorship Care (13%, 9.8%). The third most frequent goal for Course 1 was Evaluation of Survivor Needs. For course 2 the third most frequent goals were Evaluation of Survivor Needs and Team Development. Goal achievements for course 1: 70% completed or in process, 4.4% stalled or stopped and 25% never started. Course 2: 62% completed or in process, 18.3% stalled or stopped and 20% never started. Conclusions: While participants from our 2 first courses represented a variety of academic and community settings, their goals were quite similar and reflected the basic need for staff education and plans for clinical services. Barriers to success were met by approximately 29% of the participants in Course 1 &amp; approximately 38% in Course 2. These data demonstrate that Survivorship remains in the early stages as a formal period of care and ongoing development of experts/resources continues to be needed. Identification of barriers and facilitators to address them is critical.
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial
Authors: Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pere Barba, Rodrigo Martino, Pau Montesinos, Susana Vives, MªJosé Moreno, Beatriz Soria, Cristina Gil, José González-Campos, MªLuz Amigo, Andrés Novo, Mar Tormo, Arancha Bermúdez, Alfons Serrano, Teresa Bernal, Aurelio López, Juan Bergua, Lourdes Escoda, Pilar Martínez, Natalia Alonso, Santiago Mercadal, Eugenia Abella, Ramon Guàrdia, Ferran Vall-llovera, Antònia Cladera, Jordi Esteve, Raimundo García-Boyero, Evarist Feliu, Alberto Orfao
Journal: Blood (2015)
Combined Na/Ca exchanger and L-type calcium channel block by SEA-0400 suppresses Torsade de pointes arrhythmias with maintained haemodynamics
Authors: V. J. A Bourgonje, M. A Vos, Saliha Ozdemir, K Acsai, Nicolas Doisne, R Van der Nagel, H. D. M Beekman, T. A. B Van Veen, Karin Sipido, G Antoons
Journal: Cardiovascular Research (2012)
Zika virus in semen and spermatozoa
Authors: Jean Michel Mansuy, Elsa Suberbielle, Sabine Chapuy-Regaud, Catherine Mengelle, Louis Bujan, Bruno Marchou, Pierre Delobel, Daniel Gonzalez-Dunia, Cécile E Malnou, Jacques Izopet, Guillaume Martin-Blondel
Journal: The Lancet Infectious Diseases (2016)
Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973–981
Authors: Louis Monnier, Claude Colette, David R. Owens
Journal: Diabetes Care (2016)

Achieving near-normal glucose homeostasis infers that all components of dysglycemia that are present in diabetic states should be eradicated. At present, there is incontrovertible evidence that controlling chronic glucose exposure exerts consistent benefit on the incidence of all related diabetes complications (1,2). However, we are sadly lacking similar evidence for implicating glucose variability (GV) as an independent causative factor for vascular complications in those with diabetes. In an attempt to answer this question, the investigators of the FLuctuATion reduction with inSUlin and GLP-1 Added togetheR (FLAT-SUGAR) trial (3) have randomly assigned patients with insulin-requiring type 2 diabetes to two basal-prandial therapeutic protocols. The first one was the classic basal-bolus insulin …
Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: A double-blind randomised study
Authors: S. Loibl, K. Schwedler, G. von Minckwitz, R. Strohmeier, K. M. Mehta, M. Kaufmann
Journal: Journal of Clinical Oncology (2005)

8038 Background: Breast cancer patients are more susceptible to severe hot flashes due to the cytotoxic and endocrine treatment. This is one of the unsolved problems in cancer treatment because classical hormone replacement therapy is contraindicated in breast cancer especially in endocrine responsive disease. Patients and Methods: In a double blind, randomised phase III study 80 consecutive breast cancer patients (pts) who had hot flashes at least twice a day, and were not taking any medication against hypertension and depressions received either clonidine 0.075mg b.d. or venlafaxine 37.5mg b.d for four weeks. The primary endpoint is defined as frequency of hot flashes at week 5. The sample size in each group is 35 with alpha 0.1, one-sided significance level and 80% power. The null-hypothesis is defined as no difference between the groups, and the alternative hypothesis assumes a difference of 20%. A self reported one week hot flash and other symptom questionnaire was kept prior to the start of treatment until the end of the treatment course. Results: From 4/02–10/04 80 pts. were recruited of whom 69 were evaluable. 34 received clonidine and 35 venlafaxine, 4 pts. stopped early because of side effects and 7 pts. went missing. The median age was 53 years (range 35–76). All hot flashes were assigned a grade of 1, 2, 3 or 4 for mild, medium, severe and very severe, respectively. There was no difference in severity or frequency of hot flashes between the two groups at baseline. At the end of week four the reduction of hot flashes with clonidine was 37% vs. 56% with venlafaxine (P=0.001). Conclusion: Both drugs reduce hot flashes significantly. However, venlafaxine is significantly more effective in reducing hot flashes in breast cancer pts. than clonidine. No significant financial relationships to disclose.
Caspase-8 in Liver Parenchymal Cells (Lpc), but Not Rip3, is an Essential Orchestrator of Experimental Cholestatic Liver Disease
Authors: F.J. Cubero, J. Peng, M. Hatting, G. Zhao, M.E. Zoubek, R. Macias-Rodriguez, A. Ruiz-Margain, J. Reissing, H.W. Zimmermann, N. Gassler, T. Luedde, C. Liedtke, C. Trautwein
Journal: Journal of Hepatology (2016)
Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis
Authors: C. Hezode, P. Almasio, S. Bourgeois, P. Buggisch, A. Brown, M. Diago, Y. Horsmans, L. Serfaty, F. Szalay, G.B. Gaeta, R. Planas, M. Schlag, I. Lonjon-Domanec, L. Gilles, R. DeMasi, S. Zeuzem
Journal: Journal of Hepatology (2016)
Clinical Significance of Serum Hepcidin-25 Levels on Early Treatment-Related Complications after Hematopoietic Stem Cell Transplantation
Authors: Junya Kanda, Chisaki Mizumoto, Hiroshi Kawabata, Tatsuo Ichinohe, Hideyuki Tsuchida, Naohisa Tomosugi, Keitaro Matsuo, Tadakazu Kondo, Takayuki Ishikawa, Takashi Uchiyama
Journal: Blood (2008)
Does Antiviral Treatment Affect the Clinical Long-Term Outcome of Hepatitis Delta?
Authors: A. Wranke, B.C. Serrano, B. Heidrich, J. Kirschner, B. Bremer, S. Hardtke, K. Deterding, K. Port, M. Cornberg, M.P. Manns, H. Wedemeyer
Journal: Journal of Hepatology (2016)
471P Prognostic impact of lymphovascular invasion and C-MET overexpression in resected stage IB NSCLC
Authors: I.H. Kim, J.H. Kang, S.H. Hong, I.H. Lee, J.K. Park, S.H. Sung, S.J. Kim, Y.K. Kim, K.-Y. Lee, T.-J. Kim, Y.S. Kim, D.H. Han, I.R. Yoo, J.-O. Kim
Journal: Annals of Oncology (2015)
Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG.
Authors: Volker Diehl, C. Brillant, A. Engert, J. Wolf, L. Nogova, R.-P. Mueller, H. Eich, H.K. Mueller Hermelink, R. Herrman, J. Markova, A. Ho, W. Hiddemann, B. Doerken, R. Greil, B. Pfistner
Journal: Blood (2004)
O062 : Factors associated with spontaneous clearance of chronic hepatitis C virus infection: A retrospective case control study
Authors: N. Bulteel, P. Partha Sarathy, E. Forrest, H. Innes, P. Mills, H. Valerio, A. Stanley, R.N. Gunson, C. Aitken, J. Morris, S.T. Barclay
Journal: Journal of Hepatology (2015)
Influence of HIV-1 Co-Receptor Tropism on Liver Fibrosis in HIV-Infected Patients
Authors: A. Saracino, A. Cozzi-Lepri, F. Ceccherini Silberstein, S. Nozza, A. Di Biagio, G. Cassola, G. Bruno, M. Capobianchi, L. Monno, A. d’Arminio Monforte
Journal: Journal of Hepatology (2016)
Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy
Authors: Byung-Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Teresa McQueen, Marina Protopopova, Jorge E. Cortes, Joe Marszalek, Sheng-Bin Peng, Richard Eric Davis, Donald Thornton, Michael Andreeff, Marina Konopleva
Journal: Blood (2014)
Late Acute Rejection: Histological Appraisal in Different Time Periods following Liver Transplantation
Authors: A. Rastogi, V. Pamecha, G. Ramakrishna, A. Kumar, C. Bihari, G. Kumar, S.K. Sarin, A. Rastogi, V. Pamecha, G. Ramakrishna, A. Kumar, C. Bihari, G. Kumar, S.K. Sarin
Journal: Journal of Hepatology (2016)
Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting
Authors: D. Di Paolo, P. Rossi, I. Lenci, M. Milana, C. Masetti, F. Santopaolo, R. Lionetti, G. D’Offizi, A. Pellicelli, L. Fondacaro, M. Siciliano, A. Tortora, F. Chiesara, A. Moretti, F. Ceccherini-Silberstain, V. Cento, C.F. Perno, M. Angelico
Journal: Journal of Hepatology (2016)
Association of Peripheral Blood Levels of Brain-Derived Neurotrophic Factor With Autism Spectrum Disorder in Children
Authors: Xiao-Yan Qin, Jin-Chao Feng, Chang Cao, Huan-Tong Wu, Y. Peng Loh, Yong Cheng
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) may be implicated in the developmental outcomes of children with autism spectrum disorder (ASD). <h3>Objective</h3> To use meta-analysis to determine whether children with ASD have altered peripheral blood levels of BDNF. <h3>Data Source</h3> A systematic search of PubMed, PsycINFO, and Web of Science was performed for English-language literature through February 7, 2016. The search terms included<i>brain-derived neurotrophic factor</i>or<i>BDNF</i>in combination with<i>autism</i>, without year restriction. Two additional records were retrieved after a review of the reference lists of selected articles. <h3>Study Selection</h3> Studies were included if they provided data on peripheral blood levels of BDNF in children with ASD and healthy control children. Studies that included adults or with overlapping samples were excluded. <h3>Data Extraction and Synthesis</h3> Data were extracted by 2 independent observers from 19 included studies. Data were pooled using a random-effects model with Comprehensive Meta-analysis software. <h3>Main Outcomes and Measures</h3> Blood levels of BDNF in children with ASD compared with healthy controls. Altered levels of BDNF were hypothesized to be related to ASD. <h3>Results</h3> This meta-analysis included 19 studies with 2896 unique participants. Random-effects meta-analysis of all 19 studies showed that children with ASD had significantly increased peripheral blood levels of BDNF compared with healthy controls (Hedges<i>g</i>, 0.490; 95% CI, 0.185-0.794;<i>P</i> = .002). Subgroup analyses in 4 studies revealed that neonates diagnosed with ASD later in life had no association with blood levels of BDNF (Hedges<i>g</i>, 0.384; 95% CI, −0.244 to 1.011;<i>P</i> = .23), whereas children in the nonneonate ASD group (15 studies) demonstrated significantly increased BDNF levels compared with healthy controls (Hedges<i>g</i>, 0.524; 95% CI, 0.206 to 0.842;<i>P</i> = .001). Further analysis showed that children in the nonneonate ASD group had increased BDNF levels in serum (10 studies) (Hedges<i>g</i>, 0.564; 95% CI, 0.168 to 0.960;<i>P</i> = .005) but not in plasma (5 studies) (Hedges<i>g</i>, 0.436; 95% CI, −0.176 to 1.048;<i>P</i> = .16). Meta-regression analyses revealed that sample size had a moderating effect on the outcome of the meta-analysis in the nonneonate group. In addition, no publication bias was found in the meta-analysis. <h3>Conclusions and Relevance</h3> Children with ASD have increased peripheral blood levels of BDNF, strengthening the clinical evidence of an abnormal neurotrophic factor profile in this population.
Analysis of tumor suppressor genes in marginal zone B-cell lymphomas: An interphase fish study
Authors: J Dierlamm, M Stefanova, Iwona Wlodarska, Lucienne Michaux, Michel Stul, Gregor Verhoef, José Thomas, Jean-Jacques Cassiman, DK Hossfeld, Anne Hagemeijer-Hausman, Chris Peeters, Herman Van den Berghe
Journal: Blood (1998)
High Levels of Monocyte Chemotactic Protein-1 (MCP-1) are Associated with Readmission Rate and Mortality in Decompensated Cirrhosis
Authors: I. Graupera, E. Solà, R. Moreira, N. Fabrellas, C. Solé, P. Huelin, G. de Prada, E. Pose, X. Ariza, A. Risso, S. Albertos, M. Morales, W. Jiménez, P. Ginés
Journal: Journal of Hepatology (2016)
The Human Leukocyte Antigen -DPA1 RS3077 TT Polymorphism is Associated with Spontaneous Clearance of HBS Antigen in Caucasians with Chronic Hepatitis B
Authors: E. Koukoulioti, J. Fischer, S. Böhm, E. Schott, B. Fülöp, R. Heyne, T. Berg, F. van Bömmel
Journal: Journal of Hepatology (2016)
Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy
Authors: Shaji Kumar, Joseph R. Mikhael, Martha Q Lacy, Betsy R. LaPlant, Francis K Buadi, David Dingli, Morie A Gertz, Teresa Miceli, Marcia Mahlman, P.Leif Bergsagel, Suzanne R Hayman, Craig B. Reeder, Angela Dispenzieri, Dennis A. Gastineau, Jeffrey Winters
Journal: Blood (2011)
A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.
Authors: Athanasios G. Galanopoulos, Anastasia Tsakiridou, Eurydiki Michalis, Theodoros Marinakis, George Gortzolidis, Athanasios Zomas, Vasilios Xanthopoulos, Ioanna Savvidou, George Theodoropoulos, Vasiliki Grigoraki, Nikolaos I. Anagnostopoulos
Journal: Blood (2005)